278 related articles for article (PubMed ID: 33068248)
1. Inhibition of CDK4/6 and autophagy synergistically induces apoptosis in t(8;21) acute myeloid leukemia cells.
Nakatani K; Matsuo H; Harata Y; Higashitani M; Koyama A; Noura M; Nishinaka-Arai Y; Kamikubo Y; Adachi S
Int J Hematol; 2021 Feb; 113(2):243-253. PubMed ID: 33068248
[TBL] [Abstract][Full Text] [Related]
2. CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity.
Yang C; Boyson CA; Di Liberto M; Huang X; Hannah J; Dorn DC; Moore MA; Chen-Kiang S; Zhou P
Cancer Res; 2015 May; 75(9):1838-45. PubMed ID: 25744718
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of a combination therapy targeting CDK4/6 and autophagy in a mouse xenograft model of t(8;21) acute myeloid leukemia.
Matsuo H; Nakatani K; Harata Y; Higashitani M; Ito Y; Inagami A; Noura M; Nakahata T; Adachi S
Biochem Biophys Rep; 2021 Sep; 27():101099. PubMed ID: 34430715
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia.
Wang L; Wang J; Blaser BW; Duchemin AM; Kusewitt DF; Liu T; Caligiuri MA; Briesewitz R
Blood; 2007 Sep; 110(6):2075-83. PubMed ID: 17537993
[TBL] [Abstract][Full Text] [Related]
5. High-throughput proteomic profiling reveals mechanisms of action of AMG925, a dual FLT3-CDK4/6 kinase inhibitor targeting AML and AML stem/progenitor cells.
Zeng Z; Ly C; Daver N; Cortes J; Kantarjian HM; Andreeff M; Konopleva M
Ann Hematol; 2021 Jun; 100(6):1485-1496. PubMed ID: 33787984
[TBL] [Abstract][Full Text] [Related]
6. Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia.
Nemoto A; Saida S; Kato I; Kikuchi J; Furukawa Y; Maeda Y; Akahane K; Honna-Oshiro H; Goi K; Kagami K; Kimura S; Sato Y; Okabe S; Niwa A; Watanabe K; Nakahata T; Heike T; Sugita K; Inukai T
Mol Cancer Ther; 2016 Jan; 15(1):94-105. PubMed ID: 26637365
[TBL] [Abstract][Full Text] [Related]
7. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of N822K T>A mutation-induced constitutive c-KIT activation in AML cells triggers apoptotic and autophagic pathways leading to death.
Xu J; Zheng J; Fu X; Wu W; Tao L; Li D; Lin D
Int J Med Sci; 2019; 16(5):757-765. PubMed ID: 31217744
[No Abstract] [Full Text] [Related]
9. Radotinib inhibits acute myeloid leukemia cell proliferation via induction of mitochondrial-dependent apoptosis and CDK inhibitors.
Heo SK; Noh EK; Gwon GD; Kim JY; Jo JC; Choi Y; Koh S; Baek JH; Min YJ; Kim H
Eur J Pharmacol; 2016 Oct; 789():280-290. PubMed ID: 27477352
[TBL] [Abstract][Full Text] [Related]
10. ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia.
Hwang DY; Eom JI; Jang JE; Jeung HK; Chung H; Kim JS; Cheong JW; Min YH
J Exp Clin Cancer Res; 2020 May; 39(1):85. PubMed ID: 32393312
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia.
Keegan K; Li C; Li Z; Ma J; Ragains M; Coberly S; Hollenback D; Eksterowicz J; Liang L; Weidner M; Huard J; Wang X; Alba G; Orf J; Lo MC; Zhao S; Ngo R; Chen A; Liu L; Carlson T; Quéva C; McGee LR; Medina J; Kamb A; Wickramasinghe D; Dai K
Mol Cancer Ther; 2014 Apr; 13(4):880-9. PubMed ID: 24526162
[TBL] [Abstract][Full Text] [Related]
12. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.
Chong QY; Kok ZH; Bui NL; Xiang X; Wong AL; Yong WP; Sethi G; Lobie PE; Wang L; Goh BC
Pharmacol Res; 2020 Jun; 156():104686. PubMed ID: 32068118
[TBL] [Abstract][Full Text] [Related]
13. Icariside II induces cell cycle arrest and differentiation via TLR8/MyD88/p38 pathway in acute myeloid leukemia cells.
Yang J; Lan J; Du H; Zhang X; Li A; Zhang X; Liu Y; Zhang J; Zhang C; Ding Y; Zhang T
Eur J Pharmacol; 2019 Mar; 846():12-22. PubMed ID: 30579933
[TBL] [Abstract][Full Text] [Related]
14. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
[TBL] [Abstract][Full Text] [Related]
15. FLT3 and CDK4/6 inhibitors: signaling mechanisms and tumor burden in subcutaneous and orthotopic mouse models of acute myeloid leukemia.
Zhang Y; Hsu CP; Lu JF; Kuchimanchi M; Sun YN; Ma J; Xu G; Zhang Y; Xu Y; Weidner M; Huard J; D'Argenio DZ
J Pharmacokinet Pharmacodyn; 2014 Dec; 41(6):675-91. PubMed ID: 25326874
[TBL] [Abstract][Full Text] [Related]
16. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
[TBL] [Abstract][Full Text] [Related]
17. CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.
Olanich ME; Sun W; Hewitt SM; Abdullaev Z; Pack SD; Barr FG
Clin Cancer Res; 2015 Nov; 21(21):4947-59. PubMed ID: 25810375
[TBL] [Abstract][Full Text] [Related]
18. Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells.
Bonelli MA; Digiacomo G; Fumarola C; Alfieri R; Quaini F; Falco A; Madeddu D; La Monica S; Cretella D; Ravelli A; Ulivi P; Tebaldi M; Calistri D; Delmonte A; Ampollini L; Carbognani P; Tiseo M; Cavazzoni A; Petronini PG
Neoplasia; 2017 Aug; 19(8):637-648. PubMed ID: 28704762
[TBL] [Abstract][Full Text] [Related]
19. The cyclin-dependent kinase 4/6 inhibitor, abemaciclib, exerts dose-dependent cytostatic and cytocidal effects and induces autophagy in multiple myeloma cells.
Iriyama N; Hino H; Moriya S; Hiramoto M; Hatta Y; Takei M; Miyazawa K
Leuk Lymphoma; 2018 Jun; 59(6):1439-1450. PubMed ID: 28918692
[TBL] [Abstract][Full Text] [Related]
20. LukS-PV induces mitochondrial-mediated apoptosis and G0/G1 cell cycle arrest in human acute myeloid leukemia THP-1 cells.
Bu S; Xie Q; Chang W; Huo X; Chen F; Ma X
Int J Biochem Cell Biol; 2013 Aug; 45(8):1531-7. PubMed ID: 23702031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
